好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain Functional Connectivity Correlates of Pain Catastrophizing in Post-traumatic Headache
Headache
S23 - Hot Topics in Headache Medicine (1:12 PM-1:24 PM)
002
To investigate whether individuals’ pain experience, as measured by the Pain Catastrophizing Scale (PCS), is associated with magnetic resonance imaging resting-state functional connectivity (rs-FC) patterns in individuals with PTH.
Post-traumatic headache (PTH) is a common and debilitating sequela following mild traumatic brain injury (mTBI). Cognitive–affective factors, such as heightened attention or negative expectations about pain, have been linked to greater pain intensity and increased risk of pain persistence. Nevertheless, brain functional connectivity patterns associated with these cognitive-affective factors in PTH are poorly understood.
Rs-FC and PCS data were collected from 112 individuals with acute PTH (mean age: 40.5 ± 15.5; 75 females/ 37 males) within 1- 60 days post-mTBI. FC across 38 predefined regions-of-interest involved in pain, attention, and emotional processing was assessed using a seed-based correlation approach, controlling for age and sex. Correlations between FC and PCS total scores and subscores (rumination, helplessness, magnification) were investigated using linear regression corrected for multiple testing using Benjamini and Hochberg (FDR) with significance levels set as p < 0.05.

The mean PCS total score of the study population was 12.9 ± 10.6. Higher PCS scores were associated with hyperconnectivity between left amygdala and right cerebellum (raw p-value 0.0002; FDR p-value 0.0484; beta 0.0073). There were not significant associations between FC with PCS subscores.  

This finding suggests that cognitive-affective components of pain assessed using the PCS is associated with stronger FC among regions primarily involved in emotional (amygdala) and sensory–motor processing (cerebellum) in individuals with acute PTH. The identified strengthening of connectivity may amplify pain perception through heightened integration of affective and sensory signals. Overall, this study provides a novel insight into the neurobiological mechanisms contributing to maladaptive pain processing in individuals with PTH and suggests possible neural pathways involved in pain persistence.
Authors/Disclosures
Catherine D. Chong, PhD, FAAN
PRESENTER 		Dr. Chong has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HCOP.
Simona Nikolova, PhD (Mayo Clinic) Dr. Nikolova has nothing to disclose.
Gina Dumkrieger, PhD (Mayo Clinic) Gina Dumkrieger has received personal compensation for serving as an employee of Mayo Clinic. The institution of Gina Dumkrieger has received research support from NIH. The institution of Gina Dumkrieger has received research support from DOD. The institution of Gina Dumkrieger has received research support from AMGEN.
Michael R. Leonard, CCRP Mr. Leonard has nothing to disclose.
Dani Smith, MS Miss Smith has nothing to disclose.
Todd J. Schwedt, MD, FAAN (Mayo Clinic) Dr. Schwedt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Schwedt has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Schwedt has stock in Aural Analytics. Dr. Schwedt has stock in Nocira. Dr. Schwedt has stock in Allevalux. The institution of Dr. Schwedt has received research support from National Institutes of Health. The institution of Dr. Schwedt has received research support from United States Department of Defense. The institution of Dr. Schwedt has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Schwedt has received research support from SPARK Neuro. The institution of Dr. Schwedt has received research support from Henry Jackson Foundation. The institution of Dr. Schwedt has received research support from Pfizer. The institution of Dr. Schwedt has received research support from National Headache Foundation. The institution of Dr. Schwedt has received research support from American Heart Association. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received publishing royalties from a publication relating to health care.
Federico Bighiani, MD Dr. Bighiani has nothing to disclose.